Risk of Early-Onset Neonatal Infection with Maternal Infection or Colonization: A Global Systematic Review and Meta-Analysis

Download PDF České info

Background:
Neonatal infections cause a significant proportion of deaths in the first week of life, yet little is known about risk factors and pathways of transmission for early-onset neonatal sepsis globally. We aimed to estimate the risk of neonatal infection (excluding sexually transmitted diseases [STDs] or congenital infections) in the first seven days of life among newborns of mothers with bacterial infection or colonization during the intrapartum period.

Methods and Findings:
We searched PubMed, Embase, Scopus, Web of Science, Cochrane Library, and the World Health Organization Regional Databases for studies of maternal infection, vertical transmission, and neonatal infection published from January 1, 1960 to March 30, 2013. Studies were included that reported effect measures on the risk of neonatal infection among newborns exposed to maternal infection. Random effects meta-analyses were used to pool data and calculate the odds ratio estimates of risk of infection. Eighty-three studies met the inclusion criteria. Seven studies (8.4%) were from high neonatal mortality settings. Considerable heterogeneity existed between studies given the various definitions of laboratory-confirmed and clinical signs of infection, as well as for colonization and risk factors. The odds ratio for neonatal lab-confirmed infection among newborns of mothers with lab-confirmed infection was 6.6 (95% CI 3.9–11.2). Newborns of mothers with colonization had a 9.4 (95% CI 3.1–28.5) times higher odds of lab-confirmed infection than newborns of non-colonized mothers. Newborns of mothers with risk factors for infection (defined as prelabour rupture of membranes [PROM], preterm <37 weeks PROM, and prolonged ROM) had a 2.3 (95% CI 1.0–5.4) times higher odds of infection than newborns of mothers without risk factors.

Conclusions:
Neonatal infection in the first week of life is associated with maternal infection and colonization. High-quality studies, particularly from settings with high neonatal mortality, are needed to determine whether targeting treatment of maternal infections or colonization, and/or prophylactic antibiotic treatment of newborns of high risk mothers, may prevent a significant proportion of early-onset neonatal sepsis.

Please see later in the article for the Editors' Summary

Published in the journal: Risk of Early-Onset Neonatal Infection with Maternal Infection or Colonization: A Global Systematic Review and Meta-Analysis. PLoS Med 10(8): e32767. doi:10.1371/journal.pmed.1001502
Category: Research Article
doi: https://doi.org/10.1371/journal.pmed.1001502

Summary

Introduction

In the last two decades, mortality among children under 5 years old has declined significantly; however, neonatal mortality has not declined as quickly. An estimated 3.1–3.3 million newborns die each year, accounting for 40.3% of under-five mortality [1],[2]. The neonatal mortality rate, the number of newborns dying in the first 28 d of life per 1,000 live births, is estimated globally to be approximately 23.9. In low-middle income African, Eastern Mediterranean, and southeast Asian countries, the neonatal mortality rate ranges from 30.7–35.9, which is substantially greater than in high-income countries where it is estimated to be 3.6 [2].

Neonatal infections, defined as bacteremia/sepsis, pneumonia, and meningitis, cause approximately 23.4% of neonatal deaths worldwide each year [1]. Approximately half of the deaths caused by sepsis or pneumonia occur during the first week of life [3]. Over the last decade, there has been no measurable reduction in early neonatal mortality [4]. To develop research priorities and develop strategies for prevention, the mechanisms by which newborns are acquiring infection need to be better understood.

The shared relationship between mothers and their newborns leads to common risk factors and etiologies of infectious diseases. Newborns may acquire early-onset neonatal infection “vertically” (mother-to-newborn during birth) from endogenous bacteria in the mother's reproductive tract (hereafter referred to as maternal colonization), which may or may not cause disease in the mother but can cause disease in the newborn. These bacteria, often common colonizers in the maternal vaginal tract, may be transmitted to newborns during the delivery process when newborns come into direct contact with bacterial flora. Ascending infections from the mother to the fetus may occur before or during labour when colonized bacteria from the maternal perineum spread through the vaginal canal, amniotic sac, and into the once-sterile amniotic fluid [5],[6]. Amniotic fluid infection, or chorioamnionitis, and bacteremia are additional sources of bacterial transmission from the mother to fetus in utero.

In resource-rich settings, interventions such as risk-based antibiotic prophylaxis during labour (based on microbiological screening or risk factors in pregnancy), early diagnosis of sepsis, and neonatal antibiotic treatment have been highly effective in reducing mortality from early-onset neonatal bacterial sepsis [7]. As a result, in regions with low neonatal mortality levels (less than 15 per 1,000 births), such as the Americas, Europe, and western Pacific, sepsis accounts for 9.1%–15.3% of neonatal deaths [1]. Most of these cases are related to nosocomial infections or prematurity. In contrast, in resource-poor settings where neonatal mortality levels are high (more than 27 per 1,000 births), sepsis accounts for 22.5%–27.2% of neonatal deaths [1]. Interventions such as risk-based prophylaxis are rare or absent, and consequently there is a disproportionately large number of neonatal deaths from sepsis in countries like India, Nigeria, the Democratic Republic of the Congo, Pakistan, and China [1]. Newborns in very high-mortality settings are twice as likely to die from infectious diseases as in low-mortality settings. Despite the heavy burden of disease in high-mortality settings, the risk factors and modes of transmission for neonatal infections have not been well studied in these settings [8].

Several reviews have evaluated the effect of antibiotics on maternal Group B streptococcus (GBS) colonization and maternal risk factors of infection on neonatal sepsis [9]–[11]. These reviews are limited to randomized controlled trials, predominantly represented high income settings, and focused on specific maternal factors (GBS colonization, prelabour rupture of membranes [PROM], preterm prelabour rupture of membranes [PPROM]). Antibiotics given to women with PROM reduced the risk of neonatal infection (relative risk [RR] = 0.67, 95% CI 0.52–0.85) [10]. Similarly, among women with PPROM, antibiotics reduced the risk of neonatal infection (RR = 0.61, CI = 0.48–0.77) [9]. The evidence for antibiotics given during labour to prevent GBS early-onset neonatal sepsis was inconclusive [11].

This systematic review and meta-analysis estimates the risk of early-onset neonatal infection among newborns of mothers with bacterial infection or colonization compared to newborns of mothers without infection or colonization.

Methods

Definitions and Classification

Although laboratory-confirmed infections are considered the gold standard measure of infection, studies with biological samples would be limited in African and southeast Asian countries, causing an underestimate of the effect measure. Rather than restricting our review to studies with only lab-confirmed measures, we also included clinical signs, colonization, and risk factors for infection (maternal only) in order to best estimate the risk of neonatal infection. Including various measures of infection allows us to understand how different measures may affect the estimate. Following PRISMA guidelines (Text S1), we specified these definitions, our methods of analysis, and our inclusion criteria in a protocol a priori (Text S2).

We defined our exposure, maternal infection, or colonization during labor, in three categories: (i) Maternal infection: Laboratory-confirmed bacterial infection (hereafter referred to as “lab” and including bacteremia, amnionitis, urinary tract infections, or chorioamnionitis; measured by positive cultures of blood, amniotic fluid, urine, or placental swab; positive PCR—amniotic fluid only; or histopathologically confirmed chorioamnionitis) or clinical signs of infection (hereafter referred to as “signs” and including intrapartum maternal fever, uterine tenderness, maternal tachycardia, malodorous vaginal discharge, elevated white cell count, elevated C-reactive protein, physician diagnosis of clinical chorioamnionitis using a combination of the above signs, or clinical infection undefined). (ii) Maternal colonization: Positive reproductive tract/genital bacterial cultures without signs or symptoms of infection. (iii) Risk factors for infection: PROM (ROM prior to onset of labour ≥37 wk gestation), PPROM (ROM prior to onset of labour <37 wk gestation), and prolonged ROM (duration of ROM≥18–24 h or undefined).

Pregnant women without infection, reproductive tract colonization, and risk factors for infection were considered the unexposed population. The outcome, early-onset neonatal infection or colonization during the first 7 d of life, was defined in two categories: (i) Neonatal infection: Laboratory confirmed bacterial infection (“lab”, including bacteremia, meningitis, urinary tract infection, i.e., positive culture of blood, cerebrospinal fluid, or urine); clinical signs of infection (“signs”, including pneumonia, fever, hypothermia, respiratory distress, bradycardia, tachycardia, irritability, lethargy, hypotonia, seizures, poor feeding, oxygen requirement, increased frequency of apnea, poor capillary refill, metabolic acidosis, elevated white cell count, high immature-to-total neutrophil ratio, elevated C-reactive protein, or physician diagnosis of clinical sepsis using a combination of the above signs); laboratory or clinical infection (hereafter referred to as “lab/lab&signs”, including a combination of either laboratory-confirmed infection or clinical signs of infection, or undefined). (ii) Newborn colonization: positive ear canal, umbilical, axilla, or anal cultures without signs or symptoms of infection.

We use the term “maternal exposure” as an all-encompassing description of exposures and “neonatal outcome” to describe the outcomes.

The larger aim of performing this review was to determine the potential impact of an intrapartum antibiotic prophylaxis intervention by assessing the risk of vertical transmission of bacterial infection acquired through direct maternal-fetal contact via maternal reproductive tract colonization, chorioamnionitis, or trans-placental transmission (bacteremia). We decided a priori not to focus on sexually transmitted infections (such as chlamydia or syphilis) and non-bacterial infections, such as viral (HIV, rubella, cytomegalovirus, or herpes simplex) or parasitic (toxoplasmosis) infections, because they have different mechanisms of transmission.

Search Strategy and Section Criteria

We searched PubMed (Medline), Embase, Scopus, Web of Science, the Cochrane Library, and the World Health Organization (WHO) Regional Databases (African, eastern Mediterranean, Latin American and Caribbean, western Pacific, and southeast Asian regions). We developed a comprehensive search strategy focusing on three concepts: maternal infection, vertical transmission, and neonatal sepsis. We identified keyword and controlled vocabulary terms applicable to each of these concepts, then combined keywords in each database syntax. We searched studies from January 1, 1960 to March 30, 2013 with no date or language restrictions. We used the search terms as controlled vocabulary in applicable databases and as keywords in all databases (Table S1). We conducted hand searches through the reference lists of screened articles and published systematic reviews and did not find any additional articles. Source articles included publications, abstracts, and conference proceedings available in the public domain. Articles were downloaded and reviewed using EndNote (version ×4).

We included studies of any design that contained raw data or that reported effect measures on the association between maternal exposures and neonatal outcomes, even if early-onset neonatal infection was not the main aim of the study. We excluded reviews, duplicate studies, and studies without a comparison group. We also excluded studies if: the sample size was less than ten; all participants (pregnant women) received antibiotics or steroids; or the infections assessed were nonbacterial infections, tetanus infections, sexually transmitted infections such as chlamydia and syphilis, or TORCH infections (Toxoplasmosis, other, Rubella, Cytomegalovirus, Herpes simplex virus).

Screening and Data Abstraction

Two reviewers independently screened titles, abstracts, and full-text articles using predetermined selection criteria. Two data abstractors independently gathered data from included studies to assess risk of bias, classify exposures and outcomes, obtain published crude or adjusted effect measures, and select raw data to calculate effect measures. One reviewer abstracted study characteristics data. To improve data quality, a second reviewer abstracted study characteristics for a random 10% of the studies with 80% agreement. At each stage, the reviewers compared their results and resolved disagreements by reaching a consensus. We standardized and pilot tested screening and abstraction forms. For articles missing information, we contacted authors to request missing data (Table S2).

We obtained basic data on author, country, study design, and sample size. For potential subgroup analyses, we gathered data on two aspects of each study's setting: (1) health facility, multi-center, or community-based, and (2) urban versus rural. The studies provided limited data on intrapartum antibiotic use; we categorized studies according to whether the study had no intrapartum antibiotic use, some antibiotic use, or did not report antibiotic use. We considered early-onset incidence to occur during the first 7 d of life. We also included studies that examined only high risk populations such as preterm labor, PROM, PPROM, and prolonged ROM. To assess variation by region, we grouped studies by WHO region (African, southeast Asia, western Pacific, eastern Mediterranean, European, and American), 2010 World Bank gross national income per capita in US dollars (low, US$1,005 or less; lower-middle US$1,006–US$3,975; upper-middle $3,976–US$12,275; high income US$12,276 or more), and 2009 UNICEF neonatal mortality rates (very low, <5 deaths per 1,000 live births; low, 5–14 deaths/1,000; high, 15–27 deaths/1,000; and very high, more than 27 deaths/1,000) [12]–[14].

Two independent reviewers assessed the methodological quality of included studies, examining selection methods, missing data, loss-to-follow-up, and confounding bias. Reviewers gave an overall rating of high risk of bias to studies that were high risk in at least one of these domains. Reviewers categorized a study as having a low risk of bias if it qualified as low risk in at least two of these domains and was not high risk in any domain. Reviewers rated studies meeting neither the high risk nor the low risk criteria as having unclear risk.

Statistical Analysis

We used the DerSimonian and Laird [15] random-effects meta-analyses to calculate weighted mean estimates across studies and the 95% CI for the odds of neonatal infection among those exposed to maternal infection, colonization, or risk factors for infection, compared to those not exposed (Stata v12). We used the reported odds ratio (OR) and confidence interval for each study. For studies that did not report an OR, we calculated the OR and standard error from raw data. We added a standard correction of 0.5 to zero cells. We assessed measures of heterogeneity with I² statistics if there were three or more studies included in the meta-analysis. For each combination of maternal exposure and neonatal outcome, we calculated a pooled estimate of the OR. Given the substantial heterogeneity across all combinations of maternal exposures and neonatal outcomes, we did not calculate an overall pooled estimate of the ORs.

The studies we examined used numerous combinations of maternal exposure and neonatal outcome. This paper presents the following combinations: (i) maternal lab-confirmed infection and neonatal lab-confirmed infection (lab/lab); (ii) maternal lab-confirmed infection and neonatal clinical signs of infection (lab/signs); (iii) maternal lab-confirmed infection and neonatal lab or clinical infection (lab/lab&signs); (iv) maternal clinical signs of infection and neonatal lab-confirmed infection (signs/lab); (v) maternal clinical signs of infection and neonatal clinical signs of infection (signs/signs); (vi) maternal clinical signs of infection and neonatal lab or clinical infection (signs/lab&signs); (vii) maternal colonization and neonatal lab-confirmed infection (colonization/lab); (viii) maternal colonization and neonatal clinical signs of infection (colonization/signs); (ix) maternal colonization and neonatal lab or clinical infection (colonization/lab&signs); (x) maternal colonization and neonatal colonization (colonization/colonization); (xi) maternal risk factor and neonatal lab-confirmed infection (risk/lab); (xii) maternal risk factor and neonatal clinical signs of infection (risk/signs).

The four forest plots presented in this paper estimate the OR, 95% CI, and relative weights for four different groupings of these combinations: (i–vi) maternal infection and neonatal infection; (vii–ix) maternal colonization and neonatal infection; (x) maternal colonization and neonatal colonization; and (xi–xii) maternal risk factors and neonatal infections. In the forest plots, we report only ORs from cohort studies and nested case-control studies. We omitted un-nested case-control studies since we cannot approximate incidence rate ratios from them. For the studies that provided estimates adjusted for confounding factors, we present sub-group analyses with adjusted measures. These adjusted results are identified by an asterisk in the forest plot figures. In our sensitivity analyses, we repeated the meta-analyses excluding studies with (i) some or unknown intrapartum antibiotics use, (ii) high risk of bias, and (iii) late-onset neonatal cases.

We originally planned for subgroup analyses by region, gross national income per capita in US dollars stratum (low, lower-middle, upper-middle, high income), and neonatal mortality rate stratum (very low, low, high, very high). However, the scarcity of data in the lower income and higher mortality rate countries did not allow for such analyses. Instead, we describe the distribution of studies by region, income, and neonatal mortality rate. We also examined random-effects meta-regression models to investigate the effect of gross national income, neonatal mortality rate, prematurity, region on the risk of vertical transmission, and quality of studies. We repeated these analyses, assessing the effect of explanatory variables on the risk of transmission for early-onset sepsis in studies that specified measurement of infections during the first 7 d of life.

Results

Our search identified 4,712 articles of which 3,678 were unique records (Figure 1). We reviewed 448 full-text articles including 15 non-English articles (Table S3). Eighteen authors were emailed regarding missing data and provided with a sample 2×2 table to complete. Four authors responded and one [16] provided usable data. Data from 83 studies met the inclusion criteria. Our qualitative analysis included all 83 studies; our quantitative meta-analysis included 67 of them (Figure 1). Nine studies used definitions of maternal exposures or neonatal outcomes that were too heterogeneous to combine in the meta-analysis [6],[17]–[24]; these studies had ORs of neonatal outcomes among those maternally exposed compared to those unexposed between 0.5 and 194.6. Six studies used a case-control design and were excluded from the meta-analyses [25]–[30]. These six case-control studies had higher ORs than the cohort/nested case-control studies. Andrews et al. (2008) contained two zero cells and was dropped in the meta-analysis [31]. The majority of studies used cohort designs (n = 75, 90.4%) based in single health facilities (n = 64, 77.1%).

**Fig. 1. Flow diagram of study selection.**

Table 1 describes the number of studies and study characteristics in each meta-analysis. In 60 studies (72.3%), researchers measured early-onset neonatal infection outcomes during the first 7 d of life. Seventeen studies (20.5%) had data on women who all similarly did not receive intrapartum antibiotics (either the study cohort did not use antibiotics, the study excluded women who received antibiotics, or data were abstracted from the placebo arm of an intervention trial); 35 studies (42.2%) reported some antibiotic use in an undefined subset of women; and 31 studies (37.3%) did not specify whether antibiotics were used. Twenty-two of the studies (26.5%) restricted their sample to a specific target population (preterm labor, PROM, or PPROM), while the majority of studies (n = 61, 73.5%) evaluated all pregnant women. Most studies (n = 62, 74.7%) were conducted in the Americas or Europe, nine studies (10.8%) were in the western Pacific, four studies (4.8%) were in southeast Asia, six studies (7.2%) were in the eastern Mediterranean region, and two studies (2.4%) were in Africa. Most studies were in high income (n = 66, 79.5%) and very low mortality (n = 67, 80.7%) settings (Table 1). A study could report more than one type of maternal exposure or neonatal outcome but appeared only once in each meta-analysis. Table 2 lists additional details of each study. Table S4 reports the exposure and outcome definitions for each study. To assess for publication and small-study bias, we used funnel plots of standard error and effect size to determine the correlation between the variance and distribution of effect sizes (Figure S1). These results were not statistically significant (p = 0.07).

**Tab. 1. Characteristics of included studies.**

**Tab. 2. Studies included in the systematic review and meta-analysis.**

Regional

Available data on laboratory cultures, clinical signs, colonization status, and risk factors varied by region. The Americas, Europe and eastern Mediterranean regions had studies that examined all of the above measures of maternal exposure. None of the studies in Africa provided lab-confirmed maternal infection data or clinical signs data. No study in southeast Asia provided lab-confirmed data. We were able to find studies in every region that provided data on maternal colonization and risk factors for infection, although the majority were from Europe and the Americas. All regions presented data on neonatal lab-confirmed infection, with the majority in the Americas. None of the studies in Africa or the eastern Mediterranean region had neonatal clinical signs of infection. No study in southeast Asia had neonatal colonization data.

Risk of Bias

After assessing attrition bias, selection bias, and confounding bias across the 83 studies, we rated two studies (2.4%) as having low risk, 53 (63.9%) as having unclear risk, and 28 (33.7%) as having high risk of bias (Figure S2). Among the 83 studies, 15 (18.1%) studies were considered as being at high risk for attrition bias. These studies lost more than 10% of participants to follow-up or had differential follow-up between the exposed and comparison groups. Thirteen (15.7%) studies had evidence of selection bias, defined as differential selection of the exposed and comparison groups resulting in a difference in the distribution of risk factors. Sixteen (19.3%) studies were rated as being at high risk for confounding bias, defined as a lack of adjustment for potential confounders through study design or statistical adjustment.

Meta-analyses

The meta-analyses results are presented by exposure outcome combinations: (i) maternal infection and neonatal infection; (ii) maternal colonization and neonatal infection; (iii) maternal colonization and neonatal colonization; and (iv) maternal risk factors and neonatal clinical infection.

Maternal infection and neonatal infection

Twenty-nine studies reported data on maternal infections and neonatal infections. As shown in Figure 2, studies that tested lab cultures for infection in both mother and newborn (“lab/lab”), newborns of infected mothers had a 6.6 (95% CI 3.9–11.2) times greater odds of infection than newborns of uninfected mothers. In studies that diagnosed maternal infection with clinical signs and neonatal infection with lab tests (“signs/lab”), newborns of infected mothers had a 7.7 (95% CI 4.6–13.0; I² = 72.0%, 95% CI 45%–86%; adjusted OR 5.2, 95% CI 1.6–16.6; I² = 77.1%, 95% CI 25%–93%) times greater odds of infection than newborns of uninfected mothers. Studies that diagnosed neonatal infection with lab tests or clinical signs (“lab/lab&signs”; “signs/lab&signs”) had a greater OR than those that diagnosed neonatal infection with only lab or only clinical signs (“lab/lab”; “lab/signs”; “signs/lab”; “signs/signs”) (Figure 2).

Sensitivity analyses excluding studies with a high risk of bias increased the ORs to 9.3 (95% CI 5.1–16.9) for the “lab/lab” analysis and slightly decreased the OR to 6.2 (95% CI 1.7–23.1) for the “signs/lab” analysis. Excluding studies with a high risk of confounding bias yielded ORs of 9.1 (95% CI 2.4–34.0) and 7.7 (95% CI 4.6–13.0) for “lab/lab” and “signs/lab” analyses, respectively. We also conducted a sensitivity analysis including only studies that clearly defined early-onset neonatal sepsis during the first 7 d of life. The ORs increased to 10.2 (95% CI 5.3–19.5) and 8.3 (95% CI 4.5–15.1) for “lab/lab” and “signs/lab” analyses, respectively. We did not have sufficient data to conduct a sensitivity analysis subgrouping studies with known or unknown antibiotic use.

Maternal colonization and neonatal infection

Given the heterogeneity of the data, we focused on GBS maternal colonization. Sixteen studies reported data on GBS maternal colonization and neonatal infection.

As shown in Figure 3, in studies that tested GBS bacterial colonization in the mother and lab cultures for infection in the newborn (“colonization/lab”), newborns of colonized mothers had a 9.4 (95% CI 3.1–28.5; I² = 76.3%, 95% CI 58%–87%) times greater odds of having infection than newborns of non-colonized mothers. A sensitivity analysis excluding studies with high risk of bias increased the ORs to 13.7 (95% CI 4.2–45.1). Excluding studies without a specified early-onset period to measure neonatal infection increased the odds to 11.0 (95% CI 2.3–54.0). A sensitivity analysis including only studies in which no antibiotics were used also increased the OR to 37.0 (95% CI 9.7–140.9).

**Fig. 3. Maternal GBS colonization and neonatal infection.**

In studies that tested lab cultures for infection in newborns (“colonization/lab”), newborns of colonized mothers had higher odds of developing infection compared to those in studies that diagnosed neonatal infection clinical signs (“colonization/signs”) or that diagnosed neonatal infection with both lab tests and clinical signs (“colonization/lab &signs”) (Figure 3).

Maternal colonization and neonatal colonization

Twenty-five studies reported data on maternal colonization and neonatal colonization. We present these results by pathogen-specific subgroups: GBS, Staphylococcus aureus, Escherichia coli, and Ureaplasma (Figure 4). In studies that cultured GBS colonization for both the mother and newborn, newborns of colonized mothers had a 28.6 (95% CI 13.2–62.1; I² = 88.8%, 95% CI 84%–92%) times higher odds of colonization compared to newborns of non-colonized mothers.

A sensitivity analysis excluding high risk studies showed an increased OR to 43.8 (95% CI 11.0–174.8). Excluding studies that did not specify an early-onset neonatal infection period had a similar OR of 29.4 (95% CI 11.9–72.5, I² = 89.1%, 95% CI 84%–92%). The OR for Staphylococcus aureus colonization was 7.5 (95% CI 2.9–19.1). The OR for E. coli colonization was 1.8 (95% CI 1.3–2.6). One study measured Ureaplasma colonization, which had lower ORs compared to studies measuring GBS or S. Aureus colonization (Figure 4).

Maternal risk factors and neonatal infection

Ten studies presented data on maternal risk factors (PPROM, PROM, prolonged ROM) and neonatal infections (Figure 5). In studies that observed risk factors for infection in the mother and tested lab cultures for the newborn (“risk/lab”), newborns of mothers with risk factors had a 2.3 (95% CI 1.0–5.4; I² = 93.4%, 95% CI 89%–96%; adjusted OR 4.9, 95% CI 1.9–12.8) times greater odds of having infection than newborns of mothers without risk factors for infection. In two non-adjusted studies that classified PPROM as a risk factor for maternal infection and tested neonatal lab cultures for the newborn, newborns of mothers with PPROM had a 1.5 (95% CI 0.9–2.4) times greater odds of having an infection than newborns of mothers without PPROM, which was not statistically significant. In four non-adjusted studies that examined the risk factor ROM≥18–24 h, newborns of mothers with prolonged ROM had a 2.2 (95% CI 0.6–7.4) higher odds of having an infection than newborns of mothers with ROM<18 h, which was not statistically significant.

Sensitivity analysis excluding high risk of bias studies, in studies that observed risk factors for infection in the mother and tested lab cultures for the newborn (“risk/lab”), had a similar OR of 2.2 (95% CI 0.8–2.4). Similar results were seen after excluding studies without a specified early-onset neonatal sepsis period.

Meta-regression

We used meta-regression to explore the effect of potential explanatory variables on the risk of vertical transmission, including: neonatal mortality rate, gross national income, prematurity, antibiotic use, WHO region, and risk of bias in each of the four groups: maternal infection and neonatal infection, maternal colonization and neonatal infection, maternal colonization and neonatal colonization, and maternal risk factors and neonatal infection. The coefficients of all these potential explanatory variables were non-significant in the crude and adjusted analyses because of small sample sizes (Table 3).

**Tab. 3. Regression analysis of the effect of explanatory variables on the risk of transmission (early-onset).**

To examine if there were significant differences between subgroups, we conducted four meta-regression analyses testing each subgroup within the four groups: (i) maternal infection and neonatal infection, (ii) maternal colonization and neonatal infection, (iii) maternal colonization and neonatal colonization, and (iv) maternal risk factors and neonatal infections. Mothers with GBS colonization had a higher odds of having newborns with GBS colonization compared to mothers with E. coli colonization having newborns with E. coli colonization (OR = 12.9, 95% CI 1.2–143.4). There were no significant differences between other subgroups.

Discussion

We found consistent evidence of higher levels of early-onset neonatal infection among newborns of mothers with bacterial infection or colonization compared to newborns of mothers without infection or colonization. Although this relationship has long been understood, the magnitude of the disproportionate risk for infection has not yet been systematically documented. In studies with the most definitive measures of infection (“lab/lab”), newborns of infected mothers had a seven times higher odds of early-onset neonatal infection compared to newborns of uninfected mothers. Excluding high-risk-of-bias studies, the odds of neonatal infection increased to nine times higher among newborns of infected mothers compared to newborns of uninfected mothers.

We included studies that measured clinical signs or risk factors of infection and compared estimates from these studies with estimates from studies with the gold standard lab-confirmed measures. In studies that tested neonatal lab cultures and diagnosed maternal infection with clinical signs (“signs/lab”), the OR was similar (with overlapping confidence intervals) to studies that diagnosed maternal infection with lab cultures (“lab/lab”), suggesting that maternal clinical signs may reliably identify maternal infections. Future studies could test the sensitivity and specificity of using maternal clinical signs to diagnose maternal infections. In studies documenting maternal risk factors, newborns of mothers with risk factors had higher odds of infection than newborns of mothers without risk factors, although this association was weaker in studies with maternal risk factors compared to studies with maternal lab-confirmed or clinical signs of infection.

Maternal colonization with GBS has been shown to increase the odds of neonatal sepsis [32]. In this review, most studies that tested maternal colonization cultured for GBS. Colonization at delivery was associated with early-onset lab-confirmed neonatal infection, although we found a smaller effect (OR 11.0, 95% CI 3.6–33.5) than in a prior review on GBS colonization and neonatal infection published on developed countries (OR 204, 95% CI 100–419) [32]. In studies measuring maternal and neonatal colonization, there was strong evidence for increased odds of surface colonization among newborns of colonized mothers, supporting the idea that there is direct transmission through contact between the mother and newborn during delivery.

In studies with neonatal clinical signs of infection, the magnitude of the association was smaller compared to studies with neonatal lab-confirmed infection. Neonatal clinical signs may not be specific enough to detect strong associations between maternal and neonatal infections. Studies that diagnosed neonatal infection with a more comprehensive definition, neonatal lab or clinical signs of infection, had a higher OR than studies with neonatal lab alone or clinical signs alone. Laboratory cultures may underestimate the true risk of early-onset neonatal infection because their sensitivity of detecting bacteria is dependent on several factors such as the volume of the specimen collected, timing of collection, technique used, and dilution methods [33],[34].

Studies with laboratory-confirmed infections were limited, especially from African and southeast Asian regions, and this presents challenges in estimating the global risk of infection among newborns of infected mothers. Because lab-confirmed data were not available in some regions, we looked at additional measures of infection such as clinical signs of infection, risk factors for infection, and colonization with the understanding that each measure of infection varied by completeness and accuracy. While this presented a comprehensive review of the literature, it also created significant heterogeneity among the studies included in the meta-analysis. To minimize heterogeneity, we grouped studies by exposure and outcome definitions and conducted separate meta-analyses for each group. To account for additional differences, we used a random-effects model. We did not provide an overall estimate measure across all studies because we assessed the studies to be too heterogeneous. Several subgroup analyses had high I² values suggesting most of the variability across included studies is due to heterogeneity. We included pooled estimates for all subgroup analyses and I² values and I² confidence intervals to allow the reader to consider the extent of heterogeneity when interpreting these results. Since all studies were facilities-based and mostly concentrated in urban settings in the Americas and Europe, we were not able to capture the risk of neonatal infection among home births, rural births, or births at community facilities in lower-income countries, thereby limiting the generalizability of these findings.

Furthermore, most studies included in the review were assessed to be at high or unclear risk of bias, which may lead to an underestimation or overestimation of the true effect. We used sensitivity analyses to exclude high-risk-of-bias studies and specifically examined confounding bias. After excluding studies with high risk of confounding bias, the magnitude of our effect size increased, suggesting that negative confounders may have biased results towards the null. There were limited data available on intrapartum antibiotic use. The inclusion of individuals who received antibiotics would lead a study to underestimate the magnitude of the association. When possible, we conducted sensitivity analyses including only studies with data where it was clear there was no antibiotic use. Lastly, we repeated the analyses with studies that specified an early-onset neonatal period of less than 7 d, which was associated with an increased risk of transmission. Misclassification of neonatal sepsis cases in the late-onset period likely underestimated our effect size, suggesting that these cases were unlikely to be maternally acquired. Finally, classification of studies by WHO region combines disparate countries but was performed to be consistent with past literature, and limited sample sizes resulted in wide confidence intervals, limiting the precision of our estimates.

This study has important policy and research implications. The risk of early neonatal infection among women with maternal infections is high and presumably even higher in low-resource settings where most women deliver at home without access to health care. Intrapartum antibiotic prophylaxis could reduce the incidence of maternally acquired early-onset neonatal infections [7],[35],[36]. In settings where the case-fatality of early-onset neonatal sepsis is high, prophylaxis could potentially have a large benefit. Currently, a risk-based algorithm combined with GBS screening exists for use of intrapartum antibiotic prophylaxis in high income countries to prevent GBS early-onset neonatal sepsis. In this algorithm, antibiotics are given during labour to women who screened positive for GBS colonization at 35–37 wk gestation and to women with unknown GBS status and the following risk factors: less than 37 wk gestation, duration of membrane rupture ≥18 h, or temperature ≥38°C [37]. Temporal trends of decreasing GBS incidence have been observed before versus after implementation of these guidelines (1.7 per 1,000 live births in 1993 compared to 0.6 per 1,000 in 1998) [7]. This algorithm could be expanded to include other pathogens, especially in settings where GBS incidence is low such as southeast Asia (0.02 per 1,000 live births) [34]. A double-blinded randomized controlled trial testing the use of intrapartum antibiotic prophylaxis on early-onset neonatal sepsis is needed, although this would be expensive. In addition to focusing on the mother, other interventions could include administering antibiotic prophylaxis to newborns of high risk women.

Emphasis should be placed on evaluating methods to diagnose and treat maternal infections and subsequently reducing early neonatal infections. Given the available resources, or lack thereof, in regions like Africa and Asia, better diagnostics and treatment of maternal infections in these settings have the potential to substantially reduce early neonatal infections. Development of a simple algorithm that combines clinical signs and risk factors to diagnose maternal infections would be useful in settings where lab facilities (culture or colonization) are not available.

Conclusion

To our knowledge, this is the first comprehensive review looking at maternally acquired early-onset neonatal infection. Based on the results, there is great potential to reduce early-onset neonatal infections by focusing interventions on women with maternal infections (laboratory-confirmed, clinical signs), colonization, and risk factors for infection (PROM, PPROM, and prolonged ROM). There is a need to understand the etiology of both maternal infections and colonization and neonatal infections in low- and middle-income countries. Standardizing definitions for maternal infections and newborns would be helpful to compare studies. High quality studies and better diagnostics are needed in low-resource areas, especially southeast Asia and Africa.

Improving the detection of maternal infections during the intrapartum period using new technologies such as microfluidic assays, proteomic amniotic fluid analysis, or real-time polymerase chain reaction to develop point of care-devices that are cheap, fast, and highly sensitive and specific may allow health care workers to reach at-risk newborns sooner. In the meantime, improving identification of clinical signs and risk factors for maternal infection will have more immediate benefits, particularly in resource-limited settings. Although this review emphasizes targeting mothers to prevent neonatal infections, a comprehensive package would also focus on early detection of early-onset neonatal sepsis and neonatal treatment to decrease mortality and morbidity from neonatal infections during the first 7 d of life.

Supporting Information

Zdroje

1. LiuL, JohnsonHL, CousensS, PerinJ, ScottS, et al. (2012) Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 379: 2151–2161.

2. OestergaardMZ, InoueM, YoshidaS, MahananiWR, GoreFM, et al. (2011) Neonatal mortality levels for 193 countries in 2009 with trends since 1990: a systematic analysis of progress, projections, and priorities. PLoS Med 8: e1001080 doi:10.1371/journal.pmed.1001080

3. BaquiAH, DarmstadtGL, WilliamsEK, KumarV, KiranTU, et al. (2006) Rates, timing and causes of neonatal deaths in rural India: implications for neonatal health programmes. Bull World Health Organ 84: 706–713.

4. LawnJE, LeeAC, KinneyM, SibleyL, CarloWA, et al. (2009) Two million intrapartum-related stillbirths and neonatal deaths: where, why, and what can be done? Int J Gynaecol Obstet 107 Suppl 1: S5–18, S19.

5. Al-AdnaniM, SebireNJ (2007) The role of perinatal pathological examination in subclinical infection in obstetrics. Best Pract Res Clin Obstet Gynaecol 21: 505–521.

6. AyengarV, Madhulika, VaniSN (1991) Neonatal sepsis due to vertical transmission from maternal genital tract. Indian J Pediatr 58: 661–664.

7. SchragSJ, ZywickiS, FarleyMM, ReingoldAL, HarrisonLH, et al. (2000) Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 342: 15–20.

8. BangAT, BangRA, BaituleS, DeshmukhM, ReddyMH (2001) Burden of morbidities and the unmet need for health care in rural neonates–a prospective observational study in Gadchiroli, India. Indian Pediatr 38: 952–965.

9. CousensS, BlencoweH, GravettM, LawnJE (2010) Antibiotics for pre-term pre-labour rupture of membranes: prevention of neonatal deaths due to complications of pre-term birth and infection. Int J Epidemiol 39 Suppl 1: i134–143.

10. KenyonS, BoulvainM, NeilsonJP (2010) Antibiotics for preterm rupture of membranes. Cochrane Database Syst Rev CD001058.

11. OhlssonA, ShahVS (2013) Intrapartum antibiotics for known maternal Group B streptococcal colonization. Cochrane Database Syst Rev 1: CD007467.

12. World Bank (2012) GNI per capita, Atlas method. Available: http://data.worldbank.org/indicator/NY.GNP.PCAP.CD. Accessed 22 March 2012.

13. World Health Organization (2012) Global Burden of Disease Regions used for WHO-CHOICE Analyses. Available: http://www.who.int/choice/demography/regions/en/. Accessed 22 March 2012.

14. UNICEF (2011) The State of the World's Children. Table 1 basic indicators. Available: http://www.unicef.org/sowc2011/statistics.php. Accessed 26 March 2012.

15. DerSimonianR, LairdN (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.

16. PylipowM, GaddisM, KinneyJS (1994) Selective intrapartum prophylaxis for group B streptococcus colonization: management and outcome of newborns. Pediatrics 93: 631–635.

17. KalinkaJ, KrajewskiP, SobalaW, WasielaM, Brzezinska-BlaszczykE (2006) The association between maternal cervicovaginal proinflammatory cytokines concentrations during pregnancy and subsequent early-onset neonatal infection. J Perinat Med 34: 371–377.

18. KishoreKDAK (1987) SinghM (1987) BhujwalaRA (1987) Early onset neonatal sepsis–vertical transmission from maternal genital tract. Indian Pediatr 24: 45–48.

19. KunzeM, ZublerB, MullerC, FleckenU, CladA (2006) Evaluation of placental membrane swabs in the diagnosis of intrauterine infections. Geburtshilfe und Frauenheilkunde 66: 575–578.

20. MoralesWJ, AngelJL, O'BrienWF, KnuppelRA (1989) Use of ampicillin and corticosteroids in premature rupture of membranes: a randomized study. Obstet Gynecol 73: 721–726.

21. MuthusamiA, DeviCS, KanungoR, Shashikala, Srinivasan, et al. (2007) Vaginal colonization as a risk factor for the development of neonatal sepsis. Biomedicine 27: 186–188.

22. PerssonK, BjerreB, ElfstromL, PolbergerS, ForsgrenA (1986) Group B streptococci at delivery: high count in urine increases risk for neonatal colonization. Scand J Infect Dis 18: 525–531.

23. TuppurainenN, HallmanM (1989) Prevention of neonatal group B streptococcal disease: intrapartum detection and chemoprophylaxis of heavily colonized parturients. Obstet Gynecol 73: 583–587.

24. VerganiP, PataneL, ColomboC, BorroniC, GiltriG, et al. (2002) Impact of different prevention strategies on neonatal group B streptococcal disease. Am J Perinatol 19: 341–348.

25. BhuttaZA, YusufK (1997) Early-onset neonatal sepsis in Pakistan: a case control study of risk factors in a birth cohort. Am J Perinatol 14: 577–581.

26. ChemsiM, HabziA, HarrakA, BenomarS (2012) Performance of procalcitonin diagnosis of maternofetal infection. Journal de Pediatrie et de Puericulture 25: 185–192.

27. CukrowskaB, Lodinova-ZadnikovaR, SokolD, Tlaskalova-HogenovaH (1999) In vitro immunoglobulin response of fetal B-cells is influenced by perinatal infections and antibiotic treatment: a study in preterm infants. Eur J Pediatr 158: 463–468.

28. EmamghorashiF, MahmoodiN, TagarodZ, HeydariST (2012) Maternal urinary tract infection as a risk factor for neonatal urinary tract infection. Iran J Kidney Dis 6: 178–180.

29. KovoM, SchreiberL, Ben-HaroushA, ShorS, GolanA, et al. (2012) Intrapartum fever at term: clinical characteristics and placental pathology. J Matern Fetal Neonatal Med 25: 1273–1277.

30. OddieS, EmbletonND (2002) Risk factors for early onset neonatal group B streptococcal sepsis: case-control study. BMJ 325: 308.

31. AndrewsWW, SchelonkaR, WaitesK, StammA, CliverSP, et al. (2008) Genital tract methicillin-resistant Staphylococcus aureus: risk of vertical transmission in pregnant women. Obstet Gynecol 111: 113–118.

32. BenitzWE, GouldJB, DruzinML (1999) Risk factors for early-onset group B streptococcal sepsis: estimation of odds ratios by critical literature review. Pediatrics 103: e77.

33. ConnellTG, ReleM, CowleyD, ButteryJP, CurtisN (2007) How reliable is a negative blood culture result? Volume of blood submitted for culture in routine practice in a children's hospital. Pediatrics 119: 891–896.

34. EdmondKM, KortsalioudakiC, ScottS, SchragSJ, ZaidiAK, et al. (2012) Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis. Lancet 379: 547–556.

35. OhlssonA, ShahVS (2009) Intrapartum antibiotics for known maternal Group B streptococcal colonization. Cochrane Database Syst Rev (3): CD007467.

36. Saez-LlorensX, Ah-ChuMS, CastanoE, CortesL, TorresA, et al. (1995) Intrapartum prophylaxis with ceftriaxone decreases rates of bacterial colonization and early-onset infection in newborns. Clin Infect Dis 21: 876–880.

37. VeraniJR, McGeeL, SchragSJ (2010) Prevention of perinatal group B streptococcal disease–revised guidelines from CDC, 2010. MMWR Recomm Rep 59: 1–36.

38. BobittJR, LedgerWJ (1977) Unrecognized amnionitis and prematurity: a preliminary report. J Reprod Med 19: 8–12.

39. PassMA, GrayBM, DillonHCJr (1982) Puerperal and perinatal infections with group B streptococci. Am J Obstet Gynecol 143: 147–152.

40. BroekhuizenFF, GilmanM, HamiltonPR (1985) Amniocentesis for gram stain and culture in preterm premature rupture of the membranes. Obstet Gynecol 66: 316–321.

41. FeinsteinSJ, VintzileosAM, LodeiroJG, CampbellWA, WeinbaumPJ, et al. (1986) Amniocentesis with premature rupture of membranes. Obstet Gynecol 68: 147–152.

42. GauthierDW, MeyerWJ, BieniarzA (1994) Expectant management of premature rupture of membranes with amniotic fluid cultures positive for Ureaplasma urealyticum alone. Am J Obstet Gynecol 170: 587–590.

43. AverbuchB, MazorM, Shoham-VardiI, ChaimW, VardiH, et al. (1995) Intra-uterine infection in women with preterm premature rupture of membranes: maternal and neonatal characteristics. Eur J Obstet Gynecol Reprod Biol 62: 25–29.

44. MatsudaY, MaruyamaH, KurayaK (1995) Relationship between granulocyte elastase levels and perinatal infections. Gynecol Obstet Invest 39: 162–166.

45. YoonBH, RomeroR, ParkJS, KimM, OhSY, et al. (2000) The relationship among inflammatory lesions of the umbilical cord (funisitis), umbilical cord plasma interleukin 6 concentration, amniotic fluid infection, and neonatal sepsis. Am J Obstet Gynecol 183: 1124–1129.

46. GoldenbergRL, AndrewsWW, GoepfertAR, Faye-PetersenO, CliverSP, et al. (2008) The Alabama Preterm Birth Study: Umbilical cord blood Ureaplasma urealyticum and Mycoplasma hominis cultures in very preterm newborn infants. Am J Obstet Gynecol 198: 43.e41–43.e45.

47. LeeSY, CheungCW (2012) Histological chorioamnionitis - implication for bacterial colonization, laboratory markers of infection, and early onset sepsis in very-low-birth-weight neonates. J Matern Fetal Neonatal Med 25: 364–368.

48. KasperDC, MechtlerTP, ReischerGH, WittA, LanggartnerM, et al. (2010) The bacterial load of Ureaplasma parvum in amniotic fluid is correlated with an increased intrauterine inflammatory response. Diagn Microbiol Infect Dis 67: 117–121.

49. ElderHA, SantamarinaBA, SmithS, KassEH (1971) The natural history of asymptomatic bacteriuria during pregnancy: the effect of tetracycline on the clinical course and the outcome of pregnancy. Am J Obstet Gynecol 441–462.

50. McGradyGA, DalingJR, PetersonDR (1985) Maternal urinary tract infection and adverse fetal outcomes. Am J Epidemiol 121: 377–381.

51. DudleyJ, MalcolmG, EllwoodD (1991) Amniocentesis in the management of preterm premature rupture of the membranes. Aust N Z J Obstet Gynaecol 31: 331–336.

52. PuchnerT, EgarterC, WimmerC, LederhilgerF, WeichselbraunI (1993) Amniotic-Fluid Interleukin-8 as a Marker for Intraamniotic Infection. Arch Gynecol Obstet 253: 9–14.

53. de AraujoMC, SchultzR, VazFA, MassadE, FeferbaumR, et al. (1994) A case-control study of histological chorioamnionitis and neonatal infection. Early Hum Dev 40: 51–58.

54. PapantoniouNE, AntsaklisAJ, ProtopapasAG, VogiatziAI, AravantinosDI (1997) Predictive value of amniotic fluid and fetal blood cultures in pregnancy outcome in preterm prelabour rupture of membranes. J Obstet Gynaecol 17: 18–22.

55. RonnestadA, AbrahamsenTG, MedboS, ReigstadH, LossiusK, et al. (2005) Septicemia in the first week of life in a Norwegian national cohort of extremely premature infants. Pediatrics 115: e262–268.

56. DuttaS, ReddyR, SheikhS, KalraJ, RayP, et al. (2010) Intrapartum antibiotics and risk factors for early onset sepsis. Arch Dis Child Fetal Neonatal Ed 95: F99–103.

57. PuopoloKM, DraperD, WiS, NewmanTB, ZupancicJ, et al. (2011) Estimating the probability of neonatal early-onset infection on the basis of maternal risk factors. Pediatrics 128: e1155–1163.

58. WilsonJC, LevyDL, WildsPL (1982) Premature rupture of membranes prior to term: consequences of nonintervention. Obstet Gynecol 60: 601–606.

59. NewtonER, PrihodaTJ, GibbsRS (1989) Logistic regression analysis of risk factors for intra-amniotic infection. Obstet Gynecol 73: 571–575.

60. RosemondRL, GlassCA, WingoCE (1995) Daily fetal movement and breathing assessments in the management of preterm membrane rupture. J Matern-Fetal Investigation 5: 236–239.

61. MercerBM, CarrTL, BeazleyDD, CrouseDT, SibaiBM (1999) Antibiotic use in pregnancy and drug-resistant infant sepsis. Am J Obstet Gynecol 181: 816–821.

62. TudelaCM, StewartRD, RobertsSW, WendelGDJr, StaffordIA, et al. (2012) Intrapartum evidence of early-onset group B streptococcus. Obstet Gynecol 119: 626–629.

63. DollnerH, VattenL, HalgunsetJ, RahimipoorS, AustgulenR (2002) Histologic chorioamnionitis and umbilical serum levels of pro-inflammatory cytokines and cytokine inhibitors. BJOG 109: 534–539.

64. Wójkowska-MachJ, Borszewska-KornackaM, DomańskaJ, GadzinowskiJ, GulczyńskaE, et al. (2012) Early-onset infections of very-low-birth-weight infants in Polish neonatal intensive care units. Pediatr Infect Dis J 31: 691–695.

65. KordekA, TorbeA, CzajkaR (2006) Maternal venous procalcitonin levels do not correlate with umbilical cord blood and venous blood concentrations in the neonate. J Perinat Med 34: 462–465.

66. KordekA, TorbeA, PodrazaW, LoniewskaB, Jursa-KuleszaJ, et al. (2011) Does prenatal antibiotic therapy compromise the diagnosis of early-onset infection and management of the neonate? J Perinat Med 39: 337–342.

67. BoyerKM, GadzalaCA, KellyPC (1981) Rapid identification of maternal colonization with group B streptococci by use of fluorescent antibody. J Clin Microbiol 14: 550–556.

68. ChristensenKK, SvenningsenN, DahlanderK, IngemarssonE, LindenV, et al. (1982) Relation between neonatal pneumonia and maternal carriage of group B streptococci. Scand J Infect Dis 14: 261–266.

69. TowersCV, GariteTJ, FriedmanWW, PirconRA, NageotteMP (1990) Comparison of a rapid enzyme-linked immunosorbent assay test and the Gram stain for detection of group B streptococcus in high-risk antepartum patients. Am J Obstet Gynecol 163: 965–967.

70. BurmanLG, ChristensenP, ChristensenK, FryklundB, HelgessonAM, et al. (1992) Prevention of excess neonatal morbidity associated with group B streptococci by vaginal chlorhexidine disinfection during labour. The Swedish Chlorhexidine Study Group. Lancet 340: 65–69.

71. ReganJA, KlebanoffMA, NugentRP, EschenbachDA, BlackwelderWC, et al. (1996) Colonization with group B streptococci in pregnancy and adverse outcome. VIP Study Group. Am J Obstet Gynecol 174: 1354–1360.

72. PiperJM, GeorgiouS, XenakisEM, LangerO (1999) Group B streptococcus infection rate unchanged by gestational diabetes. Obstet Gynecol 93: 292–296.

73. Namavar JahromiB, PoorarianS, PoorbarfeheeS (2008) The prevalence and adverse effects of group B streptococcal colonization during pregnancy. Arch Iran Med 11: 654–657.

74. FaroS, BrehmB, SmithF, MouzoonM, GreisingerA, et al. (2010) Screening for group B streptococcus: a private hospital's experience. Infect Dis Obstet Gynecol 2010.

75. KunzeM, ZieglerA, FlueggeK, HentschelR, ProempelerH, et al. (2011) Colonization, serotypes and transmission rates of group B streptococci in pregnant women and their infants born at a single University Center in Germany. J Perinat Med 39: 417–422.

76. BobittJR, DamatoJD, SakakiniJJr (1985) Perinatal complications in group B streptococcal carriers: a longitudinal study of prenatal patients. Am J Obstet Gynecol 151: 711–717.

77. ItakuraA, KurauchiO, MorikawaS, MatsuzawaK, MizutaniS, et al. (1996) A prospective study on the relationship between intrapartum maternal group-B streptococcal concentration and signs of infection in neonates. J Obstet Gynaecol Res 22: 101–105.

78. MaY, WuL, HuangX (2000) [Study on perinatal group B Streptococcus carriers and the maternal and neonatal outcome]. Zhonghua Fu Chan Ke Za Zhi 35: 32–35.

79. MercerBM, MiodovnikM, ThurnauGR, GoldenbergRL, DasAF, et al. (1997) Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA 278: 989–995.

80. VolumenieJL, FernandezH, VialM, LebrunL, FrydmanR (2001) Neonatal group B streptococcal infection. Results of 33 months of universal maternal screening and antibioprophylaxis. Eur J Obstet Gynecol Reprod Biol 94: 79–85.

81. MerensteinGB, ToddWA, BrownG, YostCC, LuzierT (1980) Group B beta-hemolytic streptococcus: randomized controlled treatment study at term. Obstet Gynecol 55: 315–318.

82. WeintraubZ, RegevR, IancuTC, FerneM, RabinowitzBS (1983) Perinatal group B streptococcal infections in Israel. Isr J Med Sci 19: 900–902.

83. ViscontiA, OreficiG, NotarnicolaAM (1985) Colonization and infection of mothers and neonates with group B streptococci in three Italian hospitals. J Hosp Infect 6: 265–276.

84. LiangST, LauSP, ChanSH, FokTF, MuraiT, et al. (1986) Perinatal colonization of group B streptococcus–an epidemiological study in a Chinese population. Aust N Z J Obstet Gynaecol 26: 138–141.

85. KolleeLA, SpeyerI, van KuijckMA, KoopmanR, DonyJM, et al. (1989) Prevention of group B streptococci transmission during delivery by vaginal application of chlorhexidine gel. Eur J Obstet Gynecol Reprod Biol 31: 47–51.

86. AyataA, GuvencH, FelekS, AygunAD, KocabayK, et al. (1994) Maternal carriage and neonatal colonization of group-B streptococci in labor are uncommon in Turkey. Paediatr Perinat Ep 8: 188–192.

87. SuaraRO, AdegbolaRA, BakerCJ, SeckaO, MulhollandEK, et al. (1994) Carriage of group-B streptococci in pregnant Gambian mothers and their infants. J Infect Dis 170: 1316–1319.

88. SensiniA, TissiL, VerducciN, OrofinoM, Von HunolsteinC, et al. (1997) Carriage of group B streptococcus in pregnant women and newborns: A 2-year study at Perugia General Hospital. Clinl Microbiol Infec 3: 324–328.

89. HickmanME, RenchMA, FerrieriP, BakerCJ (1999) Changing epidemiology of group B streptococcal colonization. Pediatrics 104: 203–209.

90. El-KershTA, Al-NuaimLA, KharfyTA, Al-ShammaryFJ, Al-SalehSS, et al. (2002) Detection of genital colonization of group B streptococci during late pregnancy. Saudi Med J 23: 56–61.

91. TsoliaM, PsomaM, GavriliS, PetrochilouV, MichalasS, et al. (2003) Group B streptococcus colonization of Greek pregnant women and neonates: prevalence, risk factors and serotypes. Clin Microbiol Infect 9: 832–838.

92. ErenA, KucukercanM, OguzogluN, UnalN, KaratekeA (2005) The carriage of group B streptococci in Turkish pregnant women and its transmission rate in newborns and serotype distribution. Turk J Pediatr 47: 28–33.

93. LijoiD, Di CapuaE, FerreroS, MistrangeloE, GiannattasioA, et al. (2007) The efficacy of 2002 CDC guidelines in preventing perinatal group B Streptococcal vertical transmission: a prospective study. Arch Gynecol Obstet 275: 373–379.

94. ElzbietaK, JoannaSM, JanuszW, EdytaB, TomaszK, et al. (2009) The incidence of Streptococcus Group B in 100 parturient women and the transmission of pathogens to the newborn. Ginekologia Polska 80: 285–289.

95. SeoudM, NassarAH, ZallouaP, BoghossianN, EzeddineJ, et al. (2010) Prenatal and neonatal Group B Streptococcus screening and serotyping in Lebanon: incidence and implications. Acta Obstet Gynecol Scand 89: 399–403.

96. BarcaiteE, BartuseviciusA, TamelieneR, MaleckieneL, VitkauskieneA, et al. (2012) Group B streptococcus and Escherichia coli colonization in pregnant women and neonates in Lithuania. Int J Gynaecol Obstet 117: 69–73.

97. MitsudaT, AraiK, FujitaS, YokotaS (1996) Demonstration of mother-to-infant transmission of Staphylococcus aureus by pulsed-field gel electrophoresis. Eur J Pediatr 155: 194–199.

98. PinterDM, MandelJ, HultenKG, MinkoffH, TosiMF (2009) Maternal-infant perinatal transmission of methicillin-resistant and methicillin-sensitive Staphylococcus aureus. Am J Perinatol 26: 145–151.

99. Bourgeois-NicolaosN, LucetJC, DaubieC, BenchabaF, RajguruM, et al. (2010) Maternal vaginal colonisation by Staphylococcus aureus and newborn acquisition at delivery. Paediatr Perinat Epidemiol 24: 488–491.

100. HuangYC, ChaoAS, SuLH, ChangSD (2012) A cluster of methicillin-sensitive Staphylococcus aureus colonization in a nursery. J Perinat Med 40: 307–310.

101. TamelieneR, BarcaiteE, NadisauskieneRJ, VitkauskieneA, JomantieneD, et al. (2010) Impact of maternal and neonatal risk factors on neonatal Escherichia coli colonization. Early Hum Dev 86: S75.

102. KafetzisDA, SkevakiCL, SkouteriV, GavriliS, PeppaK, et al. (2004) Maternal genital colonization with Ureaplasma urealyticum promotes preterm delivery: association of the respiratory colonization of premature infants with chronic lung disease and increased mortality. Clin Infect Dis 39: 1113–1122.

103. TafariN, Ljungh-WadstromA (1979) Consequences of amniotic fluid infections: early neonatal septicaemia. Ciba Found Symp 55–67.